nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

01.09.2014

Effects of GLP-1 in the Kidney

verfasst von: Jeppe Skov

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

The incretin hormone, glucagon-like peptide-1 (GLP-1), stimulates insulin secretion and forms the basis of a new drug class for diabetes treatment. GLP-1 has several extra-pancreatic properties which include effects on kidney function. Although renal GLP-1 receptors have been identified, their exact localization and physiological role are incompletely understood. GLP-1 increases natriuresis through inhibition of the sodium-hydrogen ion exchanger isoform 3 in the proximal tubule. This may in part explain why GLP-1 receptor agonists have antihypertensive effects. Glomerular filtration rate is regulated by GLP-1, but the mechanisms are complex and may depend on e.g. glycaemic conditions. Atrial natriuretic peptide or the renin-angiotensin system may be involved in the signalling of GLP-1-mediated renal actions. Several studies in rodents have shown that GLP-1 therapy is renoprotective beyond metabolic improvements in models of diabetic nephropathy and acute kidney injury. Inhibition of renal inflammation and oxidative stress probably mediate this protection. Clinical studies supporting GLP-1-mediated renal protection exist, but they are few and with limitations. However, acute and chronic kidney diseases are major global health concerns and measures improving renal outcome are highly needed. Therefore, the renoprotective potential of GLP-1 therapy need to be thoroughly investigated in humans.

Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–39.PubMedCrossRef

Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88(1):220–4. doi:10.1210/jc.2002-021053.PubMedCrossRef

Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004;53(3):654–62.PubMedCrossRef

Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137(7):2968–78. doi:10.1210/en.137.7.2968.PubMed

Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting. J Nucl Med. 2007;48(5):736–43. doi:10.2967/jnumed.106.038679.PubMedCrossRef

Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Bmj. 2012;344:d7771.PubMedCentralPubMedCrossRef

Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737–49. doi:10.1111/dom.12085.PubMedCrossRef

Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. The American journal of physiology. 1997;273(5 Pt 1):E981–8.PubMed

Mendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol. 2012;74(3):437–44. doi:10.1111/j.1365-2125.2012.04214.x.PubMedCentralPubMedCrossRef

10.

Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187–215. doi:10.1210/er.2011-1052.PubMedCentralPubMedCrossRef

11.

Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Current medical research and opinion. 2011;27(3):547–58. doi:10.1185/03007995.2010.549466.PubMedCrossRef

12.

Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89 (6):3055–61. doi:10.1210/jc.2003-03140389/6/3055 [pii]

13.

Skov J, Dejgaard A, Frokiaer J, Holst JJ, Jonassen T, Rittig S, et al. Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men. J Clin Endocrinol Metab. 2013;98(4):E664–71. doi:10.1210/jc.2012-3855.PubMedCrossRef

14.

Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999;34(5):795–808. doi:10.1016/s0272-6386(99)70035-1.PubMedCrossRef

15.

Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol. 2002;434(3):163–7.PubMedCrossRef

16.

Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BPM, Lessa LMA, Malnic G, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Ren Physiol. 2011;301(2):F355–F63. doi:10.1152/ajprenal.00729.2010.CrossRef

17.

Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, Hosoba M et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 2013. doi:10.1038/ki.2013.427.

18.

Carraro-Lacroix LR, Malnic G, Girardi ACC. Regulation of Na+/H + exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Ren Physiol. 2009;297(6):F1647–F55. doi:10.1152/ajprenal.00082.2009.CrossRef

19.

Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54(4):965–78. doi:10.1007/s00125-010-2028-x.PubMedCrossRef

20.

Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141(1–3):120–8. doi:10.1016/j.regpep.2006.12.016.PubMedCrossRef

21.

Pezeshki A, Muench GP, Chelikani PK. Short communication: expression of peptide YY, proglucagon, neuropeptide Y receptor Y2, and glucagon-like peptide-1 receptor in bovine peripheral tissues. J Dairy Sci. 2012;95(9):5089–94. doi:10.3168/jds.2011-5311.PubMedCrossRef

22.

Pyke C, Knudsen LB. The Glucagon-Like Peptide-1 Receptor—or Not? Endocrinology. 2013;154(1):4–8. doi:10.1210/en.2012-2124.PubMedCrossRef

23.

Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE (−/−) mice. Endocrinology. 2013;154(1):127–39. doi:10.1210/en.2012-1937.PubMedCrossRef

24.

Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003;21(6):1125–35.PubMedCrossRef

25.

Thomson SC, Kashkouli A, Singh P. Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am J Physiol-Renal Physiol. 2013;304(2):F137–F44. doi:10.1152/ajprenal.00064.2012.PubMedCentralPubMedCrossRef

26.

Hirata K, Kume S. Araki S-i, Sakaguchi M, Chin-Kanasaki M, Isshiki K et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochemical and Biophysical Research. Communications. 2009;380(1):44–9.

27.

Liu Q, Adams L, Broyde A, Fernandez R, Baron A, Parkes D. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol. 2010;9(1):32.PubMedCentralPubMedCrossRef

28.

Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol. 2012;303(7):F963–71. doi:10.1152/ajprenal.00259.2012.PubMedCentralPubMedCrossRef

29.

Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes. 2001;50(11):2530–9.PubMedCrossRef

30.

Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19(5):567–75. doi:10.1038/nm.3128.PubMedCrossRef

31.

Girardi AC, Fukuda LE, Rossoni LV, Malnic G, Reboucas NA. Dipeptidyl peptidase IV inhibition downregulates Na + − H + exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol. 2008;294(2):F414–22. doi:10.1152/ajprenal.00174.2007.PubMedCrossRef

32.

Gutzwiller JP, Hruz P, Huber AR, Hamel C, Zehnder C, Drewe J, et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion. 2006;73(2–3):142–50. doi:10.1159/000094334.PubMedCrossRef

33.

Pacheco BP, Crajoinas RO, Couto GK, Davel AP, Lessa LM, Rossoni LV, et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens. 2011;29(3):520–8. doi:10.1097/HJH.0b013e328341939d.PubMedCrossRef

34.

Thomsen K. Lithium Clearance: A New Method for Determining Proximal and Distal Tubular Reabsorption of Sodium and Water. Nephron. 1984;37(4):217–23.PubMedCrossRef

35.

Girardi AC, Di Sole F. Deciphering the mechanisms of the Na+/H + exchanger-3 regulation in organ dysfunction. American journal of physiology Cell physiology. 2012;302(11):C1569–87. doi:10.1152/ajpcell.00017.2012.PubMedCrossRef

36.

Girardi AC, Knauf F, Demuth HU, Aronson PS. Role of dipeptidyl peptidase IV in regulating activity of Na+/H + exchanger isoform NHE3 in proximal tubule cells. American journal of physiology Cell physiology. 2004;287(5):C1238–45. doi:10.1152/ajpcell.00186.2004.PubMedCrossRef

37.

Girardi AC, Degray BC, Nagy T, Biemesderfer D, Aronson PS. Association of Na (+)-H (+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem. 2001;276(49):46671–7. doi:10.1074/jbc.M106897200.PubMedCrossRef

38.

Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, et al. Long-Term Treatment of Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Diabetic Nephropathy through Improving Metabolic Anomalies in db/dB Mice. J Am Soc Nephrol. 2007;18(4):1227–38. doi:10.1681/asn.2006070778.PubMedCrossRef

39.

Persson P, Hansell P, Palm F. Tubular reabsorption and diabetes-induced glomerular hyperfiltration. Acta Physiol (Oxf). 2010;200(1):3–10. doi:10.1111/j.1748-1716.2010.02147.x.

40.

Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003;21(6):1125–35. doi:10.1097/01.hjh.0000059046.65882.49.PubMedCrossRef

41.

Varanasi A, Chaudhuri A, Dhindsa S, Arora A, Lohano T, Vora MR, et al. Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2011;17(2):192–200. doi:10.4158/ep10199.or.CrossRef

42.

Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, et al. Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats. J Pharmacol Exp Ther. 2012;340(2):248–55. doi:10.1124/jpet.111.186866.PubMedCrossRef

43.

Skov J, Holst JJ, Goetze JP, Frokiaer J, Christiansen JS. Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocrine connections. 2013. doi:10.1530/ec-13-0087.

44.

Ishibashi Y, Matsui T, Ojima A, Nishino Y, Nakashima S, Maeda S, et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc Res. 2012;84(3):395–8. doi:10.1016/j.mvr.2012.06.008.PubMedCrossRef

45.

Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes. 2012;61(11):2967–79. doi:10.2337/db11-1824.PubMedCentralPubMedCrossRef

46.

van der Zijl NJ, Moors CC, Goossens GH, Hermans MM, Blaak EE, Diamant M. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care. 2011;34(4):845–51. doi:10.2337/dc10-2224.PubMedCentralPubMedCrossRef

47.

Wang HW, Mizuta M, Saitoh Y, Noma K, Ueno H, Nakazato M. Glucagon-like peptide-1 and candesartan additively improve glucolipotoxicity in pancreatic beta-cells. Metabolism. 2011;60(8):1081–9. doi:10.1016/j.metabol.2010.11.004.PubMedCrossRef

48.

Lu HL, Wang ZY, Huang X, Han YF, Wu YS, Guo X, et al. Excitatory regulation of angiotensin II on gastric motility and its mechanism in guinea pig. Regul Pept. 2011;167(2–3):170–6. doi:10.1016/j.regpep.2011.01.004.PubMedCrossRef

49.

Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertension research : official journal of the Japanese Society of Hypertension. 2005;28(3):209–14. doi:10.1291/hypres.28.209.CrossRef

50.

Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug metabolism and disposition: the biological fate of chemicals. 2010;38(11):1944–53. doi:10.1124/dmd.110.034066.CrossRef

51.

Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia. 2006;49(4):706–12. doi:10.1007/s00125-005-0128-9.PubMedCrossRef

52.

Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55(3):566–78.PubMedCentralPubMedCrossRef

53.

Rossing P, de Zeeuw D. Need for better diabetes treatment for improved renal outcome. Kidney Int Suppl. 2011;120:S28–32. doi:10.1038/ki.2010.513.PubMedCrossRef

54.

Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M et al. Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression. The American journal of pathology. 2013;182 (1):132–41. doi:http://dx.doi.org/10.1016/j.ajpath.2012.09.016.

55.

Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD (P)H oxidases. Metabolism. 2012;61(10):1422–34. doi:10.1016/j.metabol.2012.03.002.PubMedCrossRef

56.

Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney & blood pressure research. 2012;36(1):119–30. doi:10.1159/000341487.CrossRef

57.

Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N et al. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun. 2013. doi:10.1016/j.bbrc.2013.12.049.

58.

Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis. 2012;221(2):375–82. doi:10.1016/j.atherosclerosis.2011.12.039.PubMedCrossRef

59.

Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension. 2012;60(3):833–41. doi:10.1161/hypertensionaha.112.195115.PubMedCrossRef

60.

Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism. 2011;60(9):1271–7. doi:10.1016/j.metabol.2011.01.010.PubMedCrossRef

61.

Li W, Cui M, Wei Y, Kong X, Tang L, Xu D. Inhibition of the expression of TGF-beta1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2012;30(3):749–57. doi:10.1159/000341454.CrossRef

62.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317–26. doi:10.1056/NEJMoa1307684.PubMedCrossRef

63.

Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney & blood pressure research. 2012;35(6):483–8. doi:10.1159/000337929.CrossRef

64.

Fujita H, Taniai H, Murayama H, Ohshiro H, Hayashi H, Sato S et al. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1alpha in type 2 diabetic patients with incipient nephropathy. Endocrine journal. 2013.

65.

Imamura S, Hirai K, Hirai A. The glucagon-like Peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med. 2013;231(1):57–61.PubMedCrossRef

66.

Abd El Motteleb DM, Elshazly SM. Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of l-NAME in rats: Role of GLP-1 and GLP-1 receptor. Eur J Pharmacol. 2013;720(1–3):158–65. doi:10.1016/j.ejphar.2013.10.033.PubMedCrossRef

67.

Joo KW, Kim S, Ahn SY, Chin HJ, Chae DW, Lee J, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney. BMC Nephrol. 2013;14:98. doi:10.1186/1471-2369-14-98.PubMedCentralPubMedCrossRef

68.

Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756–66. doi:10.1016/s0140-6736(11)61454-2.PubMedCrossRef

69.

Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, et al. Acute kidney injury: an increasing global concern. Lancet. 2013;382(9887):170–9. doi:10.1016/s0140-6736(13)60647-9.PubMedCrossRef

70.

Yang H, Li H, Wang Z, Shi Y, Jiang G, Zeng F. Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat. The Journal of surgical research. 2013;185(2):825–32. doi:10.1016/j.jss.2013.06.042.PubMedCrossRef

71.

Glorie LL, Verhulst A, Matheeussen V, Baerts L, Magielse J, Hermans N, et al. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2012;303(5):F681–8. doi:10.1152/ajprenal.00075.2012.PubMedCrossRef

72.

Vaghasiya J, Sheth N, Bhalodia Y, Manek R. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regul Pept. 2011;166(1–3):48–54. doi:10.1016/j.regpep.2010.08.007.PubMedCrossRef

73.

Chen YT, Tsai TH, Yang CC, Sun CK, Chang LT, Chen HH, et al. Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med. 2013;11(1):270. doi:10.1186/1479-5876-11-270.PubMedCrossRef

74.

Katagiri D, Hamasaki Y, Doi K, Okamoto K, Negishi K, Nangaku M et al. Protection of Glucagon-Like Peptide-1 in Cisplatin-Induced Renal Injury Elucidates Gut-Kidney Connection. J Am Soc Nephrol. 2013. doi:10.1681/asn.2013020134.

75.

Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64(3):317–27. doi:10.1111/j.1365-2125.2007.02890.x.PubMedCentralPubMedCrossRef

76.

Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment and the efficacy and safety of liraglutide. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2011;17(3):345–55. doi:10.4158/ep10215.ra.CrossRef

77.

Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68(6):898–905. doi:10.1111/j.1365-2125.2009.03536.x.PubMedCentralPubMedCrossRef

78.

Idorn T, Knop FK, Jorgensen M, Jensen T, Resuli M, Hansen PM et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. BMJ Open. 2013;3 (4). doi:10.1136/bmjopen-2013-002764.

79.

Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12(8):648–58. doi:10.1111/j.1463-1326.2010.01212.x.PubMedCrossRef

80.

Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal failure. Diabetes Care. 2009;32(2):e22–3. doi:10.2337/dc08-1309.PubMedCrossRef

81.

Narayana SK, Talab SK, Elrishi MA. Liraglutide-induced acute kidney injury. Practical Diabetes. 2012;29(9):380–2. doi:10.1002/pdi.1727.CrossRef

82.

Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World journal of diabetes. 2013;4(5):190–201. doi:10.4239/wjd.v4.i5.190.PubMedCentralPubMed

83.

Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515–31. doi:10.1210/er.2010-0029.PubMedCrossRef

84.

Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302(1):R75–83. doi:10.1152/ajpregu.00357.2011.PubMedCentralPubMedCrossRef

85.

Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A et al. The Renal Hemodynamic Effect of SGLT2 Inhibition in Patients with Type 1 Diabetes. Circulation. 2013. doi:10.1161/circulationaha.113.005081.

86.

Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(12):1491–9. doi:10.1093/eurheartj/ehr309.PubMedCrossRef

Titel: Effects of GLP-1 in the Kidney
verfasst von: Jeppe Skov
Publikationsdatum: 01.09.2014
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 3/2014
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-014-9287-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effects of GLP-1 in the Kidney

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Extrapancreatic effects of GLP-1 and other incretins

GLP-1R activation for the treatment of stroke: Updating and future perspectives

Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery

Gut microbiota and GLP-1

Cardiovascular and hemodynamic effects of glucagon-like peptide-1

Effects of GLP-1 on appetite and weight

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin